Medicure Inc. (Medicure) is a pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics. The Company operates in the biopharmaceutical industry segment. The Company's primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban hydrochloride) owned by its subsidiary, Medicure International, Inc. and distributed in the United States and its territories through the Company's United States subsidiary, Medicure Pharma, Inc. AGGRASTAT, a glycoprotein IIb/IIIa inhibitor (GPI), is used for the treatment of acute coronary syndrome (ACS). The Company is also engaged in the development of TARDOXAL for neurological disorders, such as Tardive Dyskinesia (TD). The Company has completed Phase IIa stage of development for TARDOXAL. The Company is also developing Transdermal AGGRASTAT, a cure for acute cardiology. Transdermal AGGRASTAT is in preclinical-stage of development.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: N/A
- Sub-Industry: N/A
- Symbol: OTCMKTS:MCUJF
- CUSIP: N/A
- Web: www.medicure.com
Capitalization:- Market Cap: $101.15 million
- Outstanding Shares: 15,566,000
Average Prices:- 52 Week Range: $4.11 - $7.96
P/E:- Trailing P/E Ratio:
- Foreward P/E Ratio: 7.19
- P/E Growth:
Sales & Book Value:- Annual Revenue: $31.97 million
- Price / Sales: 3.15
- Book Value: $1.57 per share
- Price / Book: 4.12
Profitability:- EBIDTA: $7.07 million
- Net Margins: 53.57%
- Return on Equity: 97.72%
- Return on Assets: 19.60%
Debt:- Debt-to-Equity Ratio: 1.71%
- Current Ratio: 0.60%
- Quick Ratio: 0.37%
Misc:- Average Volume: 1,679 shs.
- Beta: 0.58
- Short Ratio: 1.77
Frequently Asked Questions for Medicure (OTCMKTS:MCUJF)
What is Medicure's stock symbol?
Medicure trades on the OTCMKTS under the ticker symbol "MCUJF."
How were Medicure's earnings last quarter?
Medicure Inc. (OTCMKTS:MCUJF) issued its quarterly earnings data on Wednesday, November, 9th. The company reported $0.09 earnings per share (EPS) for the quarter. The company earned $6.29 million during the quarter. Medicure had a return on equity of 97.72% and a net margin of 53.57%. View Medicure's Earnings History.
Who are some of Medicure's key competitors?
Some companies that are related to Medicure include Kamada (KMDA), Kura Oncology (KURA), Cascadian Therapeutics (CASC), Ocular Therapeutix (OCUL), Madrigal Pharmaceuticals (MDGL), VBI Vaccines (VBIV), Gemphire Therapeutics (GEMP), Viralytics (VRACY), Athersys (ATHX), Compugen (CGEN), Neos Therapeutics (NEOS), BioDelivery Sciences International (BDSI), Conatus Pharmaceuticals (CNAT), Novelion Therapeutics (NVLN), Anavex Life Sciences Corp. (AVXL), Concord Medical Services Holdings Limited (CCM), Merrimack Pharmaceuticals (MACK) and XBiotech (XBIT).
Who are Medicure's key executives?
Medicure's management team includes the folowing people:
- Albert D. Friesen Ph.D., Chairman of the Board, President, Chief Executive Officer
- James F Kinley CA, Chief Financial Officer, Secretary
- Brent Fawkes, Director
- Gerald P. McDole, Independent Director
- Arnold Naimark, Independent Director
- Peter Quick, Independent Director
How do I buy Medicure stock?
Shares of Medicure can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Medicure's stock price today?
One share of Medicure stock can currently be purchased for approximately $6.47.
MarketBeat Community Rating for Medicure (OTCMKTS MCUJF)MarketBeat's community ratings are surveys of what our community members think about Medicure and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Medicure (OTCMKTS:MCUJF) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | No ratings tracked in the last 12 months. |
| Consensus Rating: | N/A (Score: NaN) |
| Consensus Price Target: | N/A |
Analysts' Ratings History for Medicure (OTCMKTS:MCUJF)
Show:
| Date | Firm | Action | Rating | Price Target | Details |
|---|
| 1/13/2016 | Mackie | Reiterated Rating | Buy | $8.00 |  |
(Data available from 7/24/2015 forward)
Earnings History for Medicure (OTCMKTS:MCUJF)Earnings History by Quarter for Medicure (OTCMKTS MCUJF)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/9/2016 | Q3 2016 | | $0.09 | | $6.29 million | View | N/A | |
| 1/28/2014 | Nov 2013 | | ($0.04) | | $0.78 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Medicure (OTCMKTS:MCUJF)Current Year EPS Consensus Estimate: $0.46 EPS
Next Year EPS Consensus Estimate: $0.9 EPS
Dividend History for Medicure (OTCMKTS:MCUJF)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Medicure (OTCMKTS:MCUJF)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Medicure (OTCMKTS:MCUJF)
Latest Headlines for Medicure (OTCMKTS:MCUJF)
| Source: |
|
Medicure (MCUJF) Chart for Monday, July, 24, 2017
